Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Transcept's Intermezzo Yields To FDA Concerns Over Residual Side Effects

This article was originally published in The Pink Sheet Daily

Executive Summary

Transcept's low-dose zolpidem for middle-of-the-night awakenings may need additional studies, including driving tests.

You may also be interested in...



Transcept Sees Road To Intermezzo Approval Without More Driving Studies

The company says FDA "generally agreed" with a proposal for dosing reductions and labeling changes for the middle-of-the-night insomnia drug, which has received two "complete response" letters.

Transcept Sees Road To Intermezzo Approval Without More Driving Studies

The company says FDA "generally agreed" with a proposal for dosing reductions and labeling changes for the middle-of-the-night insomnia drug, which has received two "complete response" letters.

Transcept Aims To Refile Intermezzo Insomnia NDA In Late Q4 With Highway Driving Data

FDA approved a resubmission plan that responds to concerns about inadvertent re-dosing and next-day driving impairment raised in an October "complete response" letter.

Related Content

Topics

UsernamePublicRestriction

Register

PS068683

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel